H. Klumpen

发表

Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin.

Henk-Jan Guchelaar, A. V. van Kuilenburg, D. Richel, 2007, European journal of cancer.

Gastrointestinal Cancer

G. Abou-Alfa, A. El-Khoueiry, T. Meyer, 2019, Journal of Gastroenterology and Hepatology.

Defining the Starting Dose: Should It Be mg/kg, mg/m2, or Fixed?

H. Gurney, B. Gao, H. Klumpen, 2014 .

Dose calculation of anticancer drugs

H. Gurney, B. Gao, H. Klumpen, 2008, Expert opinion on drug metabolism & toxicology.

P-123Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery

A. Lamarca, J. Valle, R. Hubner, 2015 .

Anaplastic Thyroid Carcinoma; a nationwide cohort study on incidence, treatment and survival in the Netherlands over 3 decades.

C. Rasch, E. Kapiteijn, E. N. V. Nieveen van Dijkum, 2020, European journal of endocrinology.

FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements.

M. Borad, J. Furuse, H. Chang, 2019, Journal of Clinical Oncology.

Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC).

G. Abou-Alfa, T. Meyer, R. Miksad, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).

J. Bruix, T. Yau, R. Finn, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I/II, nonrandomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab, and capecitabine in patients with metastatic pancreatic cancer.

D. Richel, J. Wilmink, S. Kordes, 2011, Journal of Clinical Oncology.

Dose calculation of anticancer drugs.

H. Gurney, B. Gao, H. Klumpen, 2008, Expert opinion on drug metabolism & toxicology.

Hepatocellular carcinoma: Dutch guideline for surveillance, diagnosis and therapy.

M. A. van den Bosch, E. Bloemena, R. D. de Man, 2014, The Netherlands journal of medicine.

742TiPPHASE 3 RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF CABOZANTINIB (XL184) VS PLACEBO IN SUBJECTS WITH HEPATOCELLULAR CARCINOMA WHO HAVE RECEIVED PRIOR SORAFENIB (CELESTIAL) (NCT01908426).

M. Colombo, J. Furuse, G. Abou-Alfa, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Joon-Oh Park, H. Harputluoglu, G. Brandi, 2023, The Lancet.

Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

G. Abou-Alfa, A. El-Khoueiry, R. Miksad, 2019, Annals of Oncology.

LBA45 Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)

A. Colao, J. Metges, R. García-Carbonero, 2022, Annals of Oncology.

Altered Dihydropyrimidine Dehydrogenase Activity Associated with Mild Toxicity in Patients Treated with 5-Fluorouracil Containing Chemotherapy

A. V. van Kuilenburg, D. Richel, L. Zoetekouw, 2008, Nucleosides, nucleotides & nucleic acids.

Transporter pumps and imatinib: A cause of pharmacokinetic resistance?

C. Liddle, H. Gurney, H. Klumpen, 2008, Cancer biology & therapy.

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

H. Harputluoglu, S. Yoon, H. Marusawa, 2023, The Lancet.

National consensus on a new resectability classification for perihilar cholangiocarcinoma - A modified Delphi method.

G. Kazemier, B. Groot Koerkamp, R. Swijnenburg, 2023, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.